Is Trending Stock McKesson Corporation (MCK) a Buy Now?

McKesson (MCK) shares have outperformed the S&P 500 and its industry over the past month, gaining 6.5%. The prescription drug distributor projects strong earnings and revenue growth, with current quarter EPS expected to rise 21.4% year-over-year and sales up 10.8%. Despite consistently beating consensus estimates and a 'B' Zacks Value Style Score indicating it trades at a discount, Zacks maintains a 'Hold' rating (Zacks Rank #3) for MCK, suggesting an in-line market performance in the near term, primarily influenced by recent minor earnings estimate revisions.

Analysis

McKesson Corporation (MCK) exhibits a strong fundamental profile, underscored by significant recent stock outperformance and robust growth metrics, yet tempered by neutral near-term analyst sentiment. The company's shares have returned +6.5% over the past month, substantially outpacing the S&P 500's +2.4% gain. This performance is supported by expectations of continued growth, with consensus estimates for the current quarter pointing to a 10.8% year-over-year revenue increase and a 21.4% rise in EPS to $8.58. Furthermore, McKesson has a track record of exceeding expectations, having surpassed consensus EPS estimates in three of the last four quarters. Despite these positive indicators and a 'B' grade for value which suggests the stock trades at a discount to its peers, the outlook is moderated by a Zacks Rank #3 (Hold). This rating is influenced by a lack of significant upward revisions to earnings estimates for the current fiscal year and a minor -0.5% downward revision for the next fiscal year, suggesting the stock may perform in-line with the broader market in the immediate future.

Key Decisions for Investors

• Given the stock's recent 6.5% outperformance against a neutral 'Hold' rating, investors may consider maintaining current positions to capture the company's solid fundamental growth, while tempering expectations for continued near-term alpha.
• Potential investors should weigh the attractive valuation and strong projected double-digit earnings and revenue growth against the recent stagnation and slight downward revision in forward earnings estimates, which could limit upside.
• Closely monitor future analyst earnings estimate revisions, as any positive shift could act as a significant catalyst, potentially upgrading the stock's outlook from its current in-line market performance expectation.